This is a preview of subscription content, log in via an institution to check access.
Reference
Gonzalez P, et al. Efficiency of nivolumab in the treatment of second-line advanced non-squamous non-small cell lung cancer (NSCLC) in Spain. 42nd European Society for Medical Oncology Congress : abstr. 1319P, 8 Sep 2017. Available from: URL: http://www.esmo.org/Conferences/ESMO-2017-Congress
Rights and permissions
About this article
Cite this article
Nivolumab cost effective for second-line treatment of NSCLC. PharmacoEcon Outcomes News 789, 25 (2017). https://doi.org/10.1007/s40274-017-4432-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4432-7